ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2025
Intranasal dupilumab improves responsiveness to steroid in an asthma mouse model.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dupilumab attenuate IL-4 and IL-13 synergistic effect on airway remodeling in asthma via blocking IL-4Rα/STAT6 axis.Scientific reports · 2026Article
- Acepromazine Reduces Airway Contraction in a Murine Model of Asthma.Clinical and experimental pharmacology & physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsThe study aimed to evaluate the efficacy of local intranasal delivery of dupilumab, a monoclonal antibody targeting IL-4Rα, in comparison to intraperitoneal delivery in a mouse model of steroid-hyporesponsive asthma, a condition characterized by limited therapeutic options.
methodsDupilumab was administered via both intranasal and intraperitoneal routes to a mouse model of steroid-hyporesponsive asthma. The efficacy of the treatment was assessed through histological evaluations of inflammation and goblet cell metaplasia, analysis of immune cell infiltration in bronchoalveolar lavage fluid via cytospin, and measurement of total airway resistance using FlexiVent. Additionally, gene and protein expression related to steroid hypo-responsiveness and tissue remodeling were analyzed.
resultsIntranasal administration of dupilumab significantly reduced inflammation and goblet cell metaplasia in the bronchial epithelium. It also led to a decrease in immune cell infiltration in bronchoalveolar lavage fluid and reduced total airway resistance. Furthermore, the intranasal dupilumab-treated group exhibited lower expression of genes and proteins associated with steroid hypo-responsiveness and tissue remodeling.
conclusionsOur findings demonstrate that intranasal administration of dupilumab not only effectively reduces inflammation but also significantly reverses steroid hypo-responsiveness and tissue remodeling, outperforming systemic delivery. Thus, local intranasal administration of dupilumab offers superior therapeutic benefits in managing steroid-hyporesponsive asthma.
Indexed as
Identifiers
39969581What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.